---
title: "Molecular Partners doses first patients in Phase 2 MP0317 combo trial for cholangiocarcinoma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293213499.md"
description: "Molecular Partners has initiated dosing in a Phase 2 trial for MP0317 combined with standard chemoimmunotherapy in advanced cholangiocarcinoma. Enrollment is on track, though no results are available yet. An update is expected at ESMO 2026, with data anticipated in 2027 and trial completion targeted for 2028."
datetime: "2026-07-20T12:23:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293213499.md)
  - [en](https://longbridge.com/en/news/293213499.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293213499.md)
generator: "portal-rs"
---

# Molecular Partners doses first patients in Phase 2 MP0317 combo trial for cholangiocarcinoma

-   Molecular Partners began dosing patients in a randomized Phase 2 trial of MP0317 with standard first-line chemoimmunotherapy in advanced cholangiocarcinoma. \* Early trial progress shows enrollment advancing as planned, with patients receiving multiple treatment cycles. \* No results have been presented yet; a trial-in-progress update is scheduled for ESMO 2026, with a data update expected in 2027. \* The study tests whether adding MP0317 can improve outcomes versus standard of care alone, aiming for deeper and longer-lasting responses. \* Trial completion is targeted for 2028, setting a multi-year timeline for clinical readouts that could shape the program’s next steps. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-004758), on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MOLN.US](https://longbridge.com/en/quote/MOLN.US.md)

## Related News & Research

- [Molecular Partners GAAP EPS of -CHF0.70](https://longbridge.com/en/news/296910213.md)
- [MOLN: MP0712 advances in SCLC trials, CD70 program announced, and cash runway extends into late 2027](https://longbridge.com/en/news/296873375.md)
- [IDEAYA targets year-end 2026 start for Phase 3 IDE849 trial in extensive-stage small cell lung cancer](https://longbridge.com/en/news/297497016.md)
- [MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026](https://longbridge.com/en/news/296862063.md)
- [Jazz secures FDA approval for Ziihera in advanced HER2+ GEA](https://longbridge.com/en/news/297028123.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**